{
    "symbol": "NVTA",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-09 22:19:11",
    "content": " In the second quarter of 2022, we generated approximately $137 million of revenue and the breakdown was as follows: approximately $81 million from oncology, including germline testing, therapy selection, PCM and Companion Diagnostics, representing a 14% growth over prior year, approximately $27 million from our women's health offerings, including NIPS, Carrier and other reproductive tests, a 27% growth over last Q2, approximately $17 million from the RareDx and other testing products, including pharmacogenetics, a 18% growth over prior year, data and platform revenue was approximately $12 million, grew 19% over last year."
}